Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Influenza HA is the primary target of neutralizing antibodies during infection, and its sequence undergoes genetic drift and shift in response to immune pressure. The receptor binding HA1 subunit of HA shows much higher sequence variability relative to the metastable, fusion-active HA2 subunit, presumably because neutralizing antibodies are primarily targeted against the former in natural infection. We have designed an HA2-based immunogen using a protein minimization approach that incorporates designed mutations to destabilize the low pH conformation of HA2. The resulting construct (HA6) was expressed in Escherichia coli and refolded from inclusion bodies. Biophysical studies and mutational analysis of the protein indicate that it is folded into the desired neutral pH conformation competent to bind the broadly neutralizing HA2 directed monoclonal 12D1, not the low pH conformation observed in previous studies. HA6 was highly immunogenic in mice and the mice were protected against lethal challenge by the homologous A/HK/68 mouse-adapted virus. An HA6-like construct from another H3 strain (A/Phil/2/82) also protected mice against A/HK/68 challenge. Regions included in HA6 are highly conserved within a subtype and are fairly well conserved within a clade. Targeting the highly conserved HA2 subunit with a bacterially produced immunogen is a vaccine strategy that may aid in pandemic preparedness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of influenza haemagglutinin at the pH of membrane fusion
Bullough, P. A., Hughson, F. M., Skehel, J. J., & Wiley, D. C. (1994) · Nature · doi:10.1038/371037a0 · Cited by 1,564 · cited 1×
“The molecule loses its helicity as the pH is lowered, confirming that HA6 does not form the extended coiled coil structure observed at the low pH for WT HA2 (6).”
BackgroundAntibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326 · cited 1×
“Broadly neutralizing HA2 stem-specific monoclonal antibodies with neutralizing activity for H1 clade viruses (14, 15) and recently for H3 subtype viruses (31) have been isolated.”
BackgroundHemagglutinin receptor binding avidity drives influenza A virus antigenic drift
Hensley, S. E., Das, S. R., Bailey, A. L., Schmidt, L. M., Hickman, H. D., Jayaraman, A., Viswanathan, K., Raman, R., Sasisekharan, R., Bennink, J. R., et al. (2009) · Science · doi:10.1126/science.1178258 · Cited by 484 · cited 1×
“Even relatively few mutations (one or two mutations) in the HA globular domain are known to abolish neutralization of the virus by antibodies (35, 36).”
Background
Cited by
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 822
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen
Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M. V., Zhu, X., Hoffman, R. M. B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., et al. (2015) · Science · doi:10.1126/science.aac7263 · Cited by 600
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Krammer, F., Pica, N., Hai, R., Margine, I., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00641-13 · Cited by 423
Burton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
Influenza virus hemagglutinin stalk-based antibodies and vaccines
Krammer, F., & Palese, P. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.07.007 · Cited by 326
Quadrivalent influenza nanoparticle vaccines induce broad protection
Boyoglu-Barnum, S., Ellis, D., Gillespie, R. A., Hutchinson, G. B., Park, Y.-J., Moin, S. M., Acton, O. J., Ravichandran, R., Murphy, M., Pettie, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03365-x · Cited by 304
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., García-Sastre, A., Moran, T. M., & Palese, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013387107 · Cited by 302
Toward a Universal Influenza Virus Vaccine: Prospects and Challenges
Pica, N., & Palese, P. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-145115 · Cited by 284
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?
Cheng, V. C. C., To, K. K. W., Tse, H., Hung, I. F. N., & Yuen, K.-Y. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05012-11 · Cited by 223
“%) than those without (27%); corticosteroid group more likely to have superinfection 306 France 208 ICU patients with ARDS; 83 received corticosteroid Corticosteroid (60.2% given within 3 days of ICU admission): hydrocortisone, 57.8%; methylprednisolone, 37.3%; prednisolone, 4.8% No significant difference in oseltamiv…”
BackgroundInfluentialDouble-layered protein nanoparticles induce broad protection against divergent influenza A viruses
Deng, L., Mohan, T., Chang, T. Z., Gonzalez, G. X., Wang, Y., Kwon, Y.-M., Kang, S.-M., Compans, R. W., Champion, J. A., & Wang, B.-Z. (2018) · Nature Communications · doi:10.1038/s41467-017-02725-4 · Cited by 189
New Vaccine Design and Delivery Technologies
Kanekiyo, M., Ellis, D., & King, N. P. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy745 · Cited by 69
“In other cases more complex manipulations such as novel loop connections and stabilizing mutations have been required; "headless" or "stabilized stem" HAs lacking the immunodominant head region are a successful example that have been shown to induce responses to the immunologically subdominant stem with broader cross-…”
Background
Metadata
- Authors
- Bommakanti, G., Citron, M. P., Hepler, R. W., Callahan, C., Heidecker, G. J., Najar, T. A., Lu, X., Joyce, J. G., Shiver, J. W., Casimiro, D. R., ter Meulen, J., Liang, X., & Varadarajan, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-07-06
- Volume
- 107
- Issue
- 31
- Pages
- 13701-13706
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1976609017
- Cited by
- 214
- References
- 3
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.